Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 12/20 | 0.41 |
| ▸ | KDR | P35968 | 4/20 | 0.38 |
| ▸ | MET | P08581 | 2/20 | 0.38 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.37 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.36 |
| ▸ | FLT1 | P17948 | 2/20 | 0.36 |
| ▸ | FLT4 | P35916 | 2/20 | 0.36 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.36 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.36 |
| ▸ | KIT | P10721 | 1/20 | 0.36 |
| ▸ | BRAF | P15056 | 1/20 | 0.36 |
| ▸ | RET | P07949 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4665748 | 0.95 | EGFR (0.42) | EGFRKDRMETFGFR1FLT1 | |
| SCHEMBL4664277 | 0.95 | EGFR (0.43) | EGFRKDRMETFGFR1FLT1 | |
| SCHEMBL4663941 | 0.92 | EGFR (0.40) | EGFRKDR | |
| SCHEMBL4666186 | 0.92 | EGFR (0.41) | EGFRIKBKETBK1 | |
| SCHEMBL4665787 | 0.90 | ABL1 (0.41) | EGFRKDRMET | |
| SCHEMBL4665886 | 0.89 | EGFR (0.37) | EGFRKDRFGFR1FLT1FLT4 | |
| SCHEMBL4665711 | 0.89 | EGFR (0.38) | EGFRKDRPIK3R1PIK3CAFLT1 | |
| SCHEMBL4664427 | 0.88 | PIK3R1 (0.44) | EGFRKDRMETPIK3R1PIK3CA | |
| SCHEMBL4665796 | 0.88 | EGFR (0.44) | EGFRKDRFGFR1FLT1FLT4 | |
| SCHEMBL4665766 | 0.87 | EGFR (0.44) | EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080242681-A1 | N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors | ALTANA PHARMA AG (DE) | 2008-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242681-A1 | N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors | MAP3K19, MAP3K6, MAP3K20 | EGFR 279/4885KDR 431/4885MET 515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.